Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DARZALEX FASPRO vs DARZALEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daratumumab is a human Ig G1κ monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. It induces tumor cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis via cross-linking. It also reduces the activity of CD38-positive immunosuppressive cells (e.g., regulatory T cells, B cells, and myeloid-derived suppressor cells).
Daratumumab is an Ig G1κ human monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. Binding to CD38 induces apoptosis via immune-mediated mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
Multiple myeloma (in combination with other agents for newly diagnosed, relapsed, or refractory disease),Light chain (AL) amyloidosis (in combination with cyclophosphamide, bortezomib, and dexamethasone)
FDA-approved: Treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone for newly diagnosed patients who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan, and prednisone for newly diagnosed patients who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for previously treated patients; in combination with bortezomib and dexamethasone for previously treated patients; in combination with pomalidomide and dexamethasone for previously treated patients; as monotherapy for patients who have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent.,Off-label: Approved indications also include light chain amyloidosis (in combination with bortezomib, cyclophosphamide, and dexamethasone) based on trial data but not yet FDA-labeled; off-label use in POEMS syndrome, primary plasma cell leukemia, and autoimmune hemolytic anemia (limited evidence).
Daratumumab 1800 mg subcutaneously over 3-5 minutes once weekly for 8 weeks, then every 2 weeks for 8 doses, then every 4 weeks thereafter. Administered in combination with hyaluronidase (fixed dose 30,000 U).
16 mg/kg intravenously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25 until disease progression. Subcutaneous formulation: 1800 mg subcutaneously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25.
Terminal elimination half-life is approximately 16 days (range 11–22 days) after subcutaneous administration of DARZALEX FASPRO, supporting once-monthly dosing due to prolonged target-mediated clearance.
Mean terminal half-life is approximately 18 days (range 12–28 days) after the last dose, supporting an every-4-week maintenance dosing interval.
Daratumumab is a monoclonal antibody; it is eliminated via intracellular catabolism into small peptides and amino acids. No specific metabolic pathways or enzymes are involved.
Daratumumab is a monoclonal antibody, eliminated primarily through intracellular catabolism via the reticuloendothelial system (RES) and target-mediated clearance. It is not metabolized by hepatic CYP450 enzymes or excreted renally. The exact catabolic pathways are not fully characterized, but involve proteolysis into small peptides and amino acids.
Daratumumab is eliminated primarily through intracellular catabolism and subsequent proteolytic degradation; renal excretion is minimal (<1% of dose as unchanged drug in urine), biliary/fecal excretion is negligible.
Daratumumab is eliminated primarily via intracellular catabolism and proteolytic degradation. No significant renal or biliary excretion occurs. Less than 1% of the dose is excreted unchanged in urine.
Daratumumab is a monoclonal Ig G1 antibody; total protein binding is primarily to serum immunoglobulins (Ig G) with no specific carrier proteins; essentially 100% bound as a therapeutic antibody.
Approximately 60–70% bound to plasma proteins; specifically to Ig G and albumin via non-specific interactions.
Volume of distribution is approximately 5.0 L (range 4.0–6.5 L) corresponding to plasma volume (0.07 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with monoclonal antibodies.
Mean volume of distribution is approximately 0.1–0.2 L/kg, indicating limited distribution beyond plasma and interstitial fluid.
Bioavailability after subcutaneous administration (DARZALEX FASPRO) is approximately 69% relative to intravenous daratumumab, based on co-formulation with recombinant human hyaluronidase.
Subcutaneous administration (with recombinant human hyaluronidase) yields an absolute bioavailability of approximately 60–70% relative to IV; the SC formulation provides comparable exposure with a 15–20% lower mean trough concentration.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Data insufficient for severe renal impairment (Cr Cl <30 m L/min) or hemodialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Data insufficient for severe (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients under 18 years. No approved dosing.
No specific dose adjustment recommended based on age alone. Monitor for adverse reactions such as infusion-related reactions and infections.
No specific dose adjustment required. Clinical studies included patients up to 85 years; overall safety and efficacy similar to younger adults, but monitor for increased adverse reactions.
None.
No FDA black box warning.
Infusion-related reactions (severe, including anaphylactic reactions) – premedicate and monitor during infusion; discontinue if severe reactions occur.,Increased risk of infections (including opportunistic infections) – monitor for signs of infection and manage promptly.,Neutropenia and thrombocytopenia – monitor blood counts regularly.,Interference with blood transfusion compatibility testing (daratumumab binds to CD38 on red blood cells) – type and screen patients prior to treatment; notify blood bank about daratumumab use.,Hepatitis B virus reactivation – screen for HBV prior to treatment; monitor during and after therapy.,Embryo-fetal toxicity – can cause fetal harm; advise contraception in females of reproductive potential.
Infusion reactions: Severe, including anaphylactic reactions, bronchospasm, hypotension, and hypoxia. Premedicate with corticosteroids, antihistamines, and antipyretics.,Hematologic toxicity: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly.,Interference with blood compatibility testing (indirect antiglobulin test): Daratumumab binds to CD38 on red blood cells, causing pan-reactivity in antibody screening tests. Type and screen must be performed prior to starting therapy.,Increased risk of infections: Bacterial, viral (including herpes zoster reactivation), and fungal infections; consider antiviral prophylaxis.,Embryo-fetal toxicity: May cause fetal harm; advise females of reproductive potential to use effective contraception.,Cardiac toxicity: Cases of cardiac arrest, arrhythmias, and heart failure; monitor patients with cardiac history.,Second primary malignancies: Increased risk of non-melanoma skin cancer and other malignancies.
None.
Absolute: history of severe hypersensitivity (e.g., anaphylaxis) to daratumumab or any of its excipients.,Relative: None specifically listed; however, caution is advised in patients with active infections, pre-existing cardiac disease, or severe renal impairment (due to limited data).
No clinically significant food interactions have been reported. Take as directed without regard to meals.
No specific food interactions are known. Maintain adequate hydration unless otherwise directed.
Daratumumab (DARZALEX FASPRO) is an Ig G1 monoclonal antibody. Ig G molecules are known to cross the placental barrier. Based on its mechanism of action (CD38-directed cytolytic activity), there is a potential for fetal B-cell depletion and immunosuppression. Animal studies are not available. Advise patients of potential fetal harm. Avoid use during pregnancy unless benefit outweighs risk. First trimester: minimal transfer; risk theoretical. Second and third trimesters: increased placental transfer; risk of fetal B-cell lymphopenia and immunosuppression.
Daratumumab is an Ig G1 monoclonal antibody. As Ig G molecules cross the placenta, especially during the third trimester, there is potential for fetal exposure. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action, daratumumab may cause fetal harm, including B-cell depletion in the fetus. Advise pregnant women of the potential risk to a fetus.
No data on the presence of daratumumab in human milk, its effects on the breastfed infant, or milk production. Daratumumab is a large protein molecule that is likely degraded in the infant gastrointestinal tract. However, consider the developmental and health benefits of breastfeeding alongside the mother's clinical need. M/P ratio: unknown.
No data on the presence of daratumumab in human milk, effects on the breastfed infant, or effects on milk production. Human Ig G is present in breast milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 3 months after the last dose. M/P ratio is unknown.
No specific pharmacokinetic studies in pregnancy. Monoclonal antibodies may have altered clearance during pregnancy due to increased plasma volume and catabolism. However, no dose adjustment is recommended currently due to lack of data. Use during pregnancy only if clearly needed; consider maternal and fetal risks.
No dose adjustment recommendations are available for pregnancy due to lack of pharmacokinetic data. Daratumumab is a monoclonal antibody with a long half-life; pregnancy may alter volume of distribution and clearance, but specific adjustments cannot be determined. Use only if the potential benefit justifies the potential risk to the fetus.
Pre-medicate with antihistamines, antipyretics, and corticosteroids to mitigate infusion-related reactions. Do not interchange Daralex Faspro (daratumumab and hyaluronidase-fihj) with intravenous daratumumab due to different dosing and administration routes. Administer subcutaneous injection in the abdomen over 3-5 minutes. Monitor for delayed infusion reactions up to 24 hours post-injection. Assess hepatitis B status before initiation; reactivation can occur. Do not administer live vaccines concurrently.
Premedicate with antihistamines, antipyretics, and corticosteroids to reduce infusion reactions. Monitor for thrombocytopenia and neutropenia. Consider herpes zoster prophylaxis due to increased risk of reactivation. Infusion rate escalation should follow standard protocol to mitigate reactions.
You will receive this medicine as an injection under your skin, usually in the belly area. The injection takes 3 to 5 minutes.,You may have reactions like fever, chills, headache, or nausea around the time of the injection; you will receive medicines to help prevent these.,Serious allergic reactions can occur; tell your healthcare provider immediately if you have difficulty breathing, chest tightness, or swelling of your face or throat.,You may have a higher risk of infections; report any signs of infection such as fever, cough, or sore throat.,Do not receive live vaccines (e.g., flu nasal spray, shingles vaccine) while on this treatment.,This medication can affect your blood counts; you will need regular blood tests.,Tell all healthcare providers you are taking Darzalex Faspro, as it may interfere with blood typing tests.
You may experience infusion reactions such as fever, chills, or shortness of breath during or after the infusion; report these immediately.,This drug lowers your platelet and white blood cell counts, increasing risk of bleeding and infection. Monitor for signs like easy bruising or fever.,You will need frequent blood tests to monitor blood counts and liver function.,Avoid live vaccines while on this medication.,Inform your healthcare provider if you have a history of shingles (herpes zoster) as preventive antiviral therapy may be needed.
No interactions on record
No interactions on record
Common clinical questions about DARZALEX FASPRO vs DARZALEX, answered by our medical review team.
DARZALEX FASPRO is a CD38-directed Monoclonal Antibody that works by Daratumumab is a human Ig G1κ monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. It induces tumor cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis via cross-linking. It also reduces the activity of CD38-positive immunosuppressive cells (e.g., regulatory T cells, B cells, and myeloid-derived suppressor cells).. DARZALEX is a CD38-directed Monoclonal Antibody that works by Daratumumab is an Ig G1κ human monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. Binding to CD38 induces apoptosis via immune-mediated mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DARZALEX FASPRO and DARZALEX depend on the specific clinical indication. These are both CD38-directed Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DARZALEX FASPRO is: Daratumumab 1800 mg subcutaneously over 3-5 minutes once weekly for 8 weeks, then every 2 weeks for 8 doses, then every 4 weeks thereafter. Administered in combination with hyaluronidase (fixed dose 30,000 U).. The standard adult dose of DARZALEX is: 16 mg/kg intravenously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25 until disease progression. Subcutaneous formulation: 1800 mg subcutaneously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DARZALEX FASPRO and DARZALEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DARZALEX FASPRO is classified as Category C. Daratumumab (DARZALEX FASPRO) is an IgG1 monoclonal antibody. IgG molecules are known to cross the placental barrier. Based on its mechanism of action (CD38-directed cytolytic acti. DARZALEX is classified as Category C. Daratumumab is an IgG1 monoclonal antibody. As IgG molecules cross the placenta, especially during the third trimester, there is potential for fetal exposure. There are no adequate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.